Valneva makes U.S. regulatory submission for one-shot chikungunya vaccine By Reuters



© Reuters. FILE PHOTO; Valneva brand is seen displayed on this illustration taken, Could 3, 2022. REUTERS/Dado Ruvic/Illustration

PARIS (Reuters) – Vaccines firm Valneva stated on Friday that it had accomplished a regulatory submission step with america Meals & Drug Administration (FDA) for its single-shot chikungunya vaccine candidate, VLA1553.

Chikungunya is a mosquito-borne viral illness. Valneva plans to make regulatory submissions for its VLA1553 vaccine in Europe within the second half of 2023.



Supply hyperlink

Leave a Reply

Your email address will not be published. Required fields are marked *